FOLLOW US

Danaher Corp. announced Tuesday it will acquire Masimo Corp. in a blockbuster $9.9 billion transaction, including debt, a move set to reshape the global diagnostics landscape. Kirkland & Ellis LLP is advising Danaher, while Sullivan & Cromwell LLP and White & Case LLP represent Masimo.

Cash Deal and Strategic Integration

Under the agreement, Danaher will pay $180 per share in cash for all outstanding Masimo common stock. After the deal closes, Masimo is expected to operate as a standalone unit within Danaher’s diagnostics segment, alongside established units such as Radiometer, Leica Biosystems, Cepheid, and Beckman Coulter Diagnostics.

Danaher CEO and President Rainer M. Blair called Masimo’s pulse oximetry and patient monitoring technologies “strategic fits” that will reinforce the company’s diagnostics capabilities. Pulse oximetry, widely used in acute care settings, measures blood oxygen levels, providing critical patient data.

“With the Danaher Business System and our global scale, we see opportunities to expand Masimo’s reach and continue improving outcomes for patients,” Blair said in a Tuesday statement.

Masimo’s Growth and Global Reach

Katie Szyman, CEO of Masimo, expressed excitement about joining forces with Danaher. “We look forward to continuing our growth and momentum as the global leader in patient monitoring,” she said. “Danaher shares our commitment to investing in talent and innovation and will be an ideal fit.”

Szyman emphasized that Masimo’s integration into Danaher’s diagnostics segment will enhance the company’s ability to scale monitoring technologies globally.

Closing Timeline and Financing

The transaction is expected to close in the second half of 2026, pending regulatory approvals and shareholder consents. Danaher plans to fund the acquisition with a mix of cash on hand and debt financing.

Danaher, headquartered in Washington, D.C., is a global life sciences and diagnostics company employing 60,000 people worldwide. Masimo, based in Irvine, California, specializes in noninvasive patient monitoring, including pulse oximetry devices critical to acute care.

Legal Advisors

The Kirkland & Ellis team representing Danaher is led by corporate partners David Klein, Brian Junquera, and Daniel Wolf. Sullivan & Cromwell’s team for Masimo is led by partners Melissa Sawyer and Lauren S. Boehmke. White & Case’s deal team information was not immediately available Tuesday.